SPRO News and Press, Spero Therapeutics Inc. From 08/03/23

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MD...

Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30 million development milestone payment from GSK CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeu...

2023-07-05 15:06:02 ET Summary Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other assets that will soon be evaluated in proof-of-concep...

2023-06-14 08:29:02 ET Spero Therapeutics ( NASDAQ: SPRO ) has announced that Satyavrat “Sath” Shukla, Spero’s current CFO and Treasurer, will serve as Spero’s President and CEO, and as a member of the Board of Directors, effective August 1, 2023. ...

Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023 Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors ...

2023-05-11 20:59:10 ET Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Ted Jenkins – Vice President, Investor Relations and Strategic Finance Ankit Mahadevia – Chief Executive Officer Sat...

2023-05-11 16:17:37 ET Spero Therapeutics press release ( NASDAQ: SPRO ): Q1 GAAP EPS of -$0.25 beats by $0.08 . Revenue of $2.07M (flat Y/Y) beats by $0.8M . For further details see: Spero Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $2.07M...

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr program expected mid-year 2023; initiation of Phase 3 trial in complicated urinary...

2023-05-10 17:35:35 ET Spero Therapeutics ( NASDAQ: SPRO ) is scheduled to announce Q1 earnings results on Thursday, May 11th, after market close. The consensus EPS Estimate is -$0.26 (+74.3% Y/Y) and the consensus Revenue Estimate is $1.27M (-38.6% Y/Y). Over the last...

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR...